AMUR MINERALS – SHARES SOAR ON GRANT OF PRODUCTION LICENCE

Amur1Amur Minerals AMC today announces that Dimitry Medvedev, the Russian Premier has signed the long awaited exploration and production licence for AMC’s huge Kun Mani project in Amur Province in far East Russia. The shares started rising early this morning before AMC issued its RNS, after news of the grant appeared in the Russian Media. So far today the shares have risen by 67% and now stand at 17p, having closed yesterday at just under 12p. The licence is for a period of 20 years.

The full text of the RNS is as follows;

Kun-Manie Production Licence Awarded

100% Production Rights

Amur Minerals Corporation (“Amur” or the “Company”), the exploration and development company focused on base metal projects located in the Far East of Russia, is delighted to report that the Government of Prime Minister Dmitry Medvedev has approved the Company’s “Detailed Exploration and Mine Production Licence” for its Kun-Manie nickel copper sulphide deposit. The new 36 square kilometre licence is valid until December 2034.

The decision by the Russian Government marks the successful completion of the production licence award process for a strategic deposit. Conclusion of the process enables the Ministry of Natural Resources (“MNR”) and Rosnedra to issue the “Detailed Exploration and Mine Production Licence” per the directive of the Russian Government. Upon registration of the final document, the Company has 30 days to submit its payment of 23.6 million Rubles (approximately $480,000) to officially complete the transaction. The licence grants our wholly owned subsidiary ZAO Kun-Manie the rights to recover all value from the mineral defined to be present at Kun-Manie.

Highlights:

· The Russian Government has approved the Company’s application for mining rights at Kun Manie and issued the directive granting the production rights to the Company until 2034,

· The Company holds 100% of the rights and is entitled to recover all economic value minerals including nickel, copper, cobalt, platinum, palladium, and other minor minerals,

All drilled mineralisation (841,000 nickel tonnes equivalent) lies within the limits of the production licence, and

· Upon receipt of the licence and as agreed in the Terms and Conditions, the Company will compensate the Government with a one-time payment of 23.6 million Roubles (approximately US$480,000).

The award of the “Detailed Exploration and Mine Production Licence” is a major milestone and initiates a new phase for the Company. The strategy of the Company can now shift from exploration to that of pre-production. Over the course of the licence award process, additional engineering work and planning has been implemented by our staff and independent consultants and will be useful in future assessment and design of the operation.

In anticipation of the award, our ZAO Kun-Manie team has already completed a “Project” (Proekt) document defining the plans and activities necessary to advance Kun-Manie to a producing operation. Submission of the programme sets out a work plan in accordance with the Terms and Conditions of the licence. Typically, companies await the final award of a production licence before completing such documentation, however by undertaking this effort in advance of the actual award, the Company will be able to register its detailed exploration plan, allowing it to take advantage of this upcoming field season and further advance the potential of Kun-Manie on a more accelerated basis. The exploration programme will define additional resources and reserves and in-fill drilling will be implemented to define the extent of the Proven and Probable reserves.

The Terms and Conditions of the licence, as negotiated with Rosnedra, set out the responsibilities of the Company to maintain the production rights in good standing. Broadly, the key points address the specifics of the following:

· The one-time payment to be made within 30 days of licence registration in the sum total of 23,610,272 Rubles (approximately $480,000).

· Annually reporting to mineral resource agencies by 15 January.

· Regular environmental monitoring requirements are included.

· Detailed exploration plans are to be provided to appropriate agencies

· Additional work related to metallurgy and engineering studies will be compiled in a final permanent TEO (Russian feasibility study) to be approved by the GKZ (State Reserves Committee), including additional results for detailed exploration.

· The detailed exploration “Project” has been drafted by the Company and will require approval by the regional authorities. It establishes the basic parameters and volumes of work for the next phase of development, in preparation for the start of production.

The newly defined boundaries of the approved 36 square kilometre “Detailed Exploration and Production Licence” are summarized below. An illustration of the production area and the former exploration licence can be viewed using the hyperlink:

Robin Young, CEO of Amur Minerals Corporation, commented:

“Today we have the distinct privilege of announcing to our shareholders that we are embarking on a new and exciting phase at the Kun-Manie nickel sulphide project with the granting of the 20 year “Detailed Exploration and Mine Production Licence”. As we prepare for the detailed exploration, engineering and subsequent production stages of the project, we express gratitude to our team in Russia and the UK, to the Russian Government for their support of the Company’s efforts, and to our shareholders, many of whom have been steadfast over the years in their belief that Kun-Manie is a highly substantial asset with a great future. We are pleased with the licence terms and conditions, which we agreed with the Government, and note that the authorities give considerable leeway to advance the project as quickly and efficiently as possible. On behalf of the Board of Amur, thank you for your unwavering support. We look forward to taking up the next phases of pre-production and development.”

HiddenGreece – villas and houses for sale in Greece – http://www.hiddengreece.net

Alan Green gives good Feedback on Feedback PLC with Justin Waite on the ADVFN podcast

FBKlogoAlan Green gives good Feedback on Feedback PLC with Justin Waite on the ADVFN podcast.

Link here to listen to the podcast

Justin Waite interviews Advanced Oncotherapy CEO Sanjeev Pandya on the ADVFN podcast

AVO1Justin Waite interviews Advanced Oncotherapy (AVO) CEO Sanjeev Pandya on the ADVFN podcast.

The interview is 3 minutes, 25 seconds in.

Link here to listen

Advanced Oncotherapy – Notice of Results

AVO1Advanced Oncotherapy (AVO) will announce its results for the year ended 31 December 2014 on Wednesday 3 June 2015.

 

A briefing for analysts will take place on the day.If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email avo@walbrookpr.com.

www.avoplc.com
Sanjeev Pandya, CEO, Nicolas Serandour, CFO Tel: +44 20 3617 8728

Westhouse Securities (Nomad & Joint Broker) Antonio Bossi / David Coaten
Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)  Saif Janjua / Jon Levinson
Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)
Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy
Mob: +44 7980 541 893 / Mob: +44 7876 741 001

Brand Communciations – Alan Green
Tel: +44 7976 431608

Medical Imaging News – Susceptibility Weighted Imaging in the Evaluation of Cerebrovascular Hemodynamics

By Carlos Zamora – Guest Editor – American Journal of Neuroradiology News Digest

Susceptibility-weighted imaging (SWI) is a high-resolution, fully velocity-compensated gradient-echo MRI sequence that maximizes intrinsic contrast differences between tissues by virtue of their local magnetic properties. This technique exploits susceptibility information contained within phase acquisitions and merges such with magnitude data to generate a clinically usable set of images.

Notably, the functional incorporation of phase data in a clinical sequence was initially challenging and warranted improvements in MRI technology that eventually culminated in the development of SWI. The entire sequence requires no more than a few minutes of scanning time and can be effectively applied in a clinical setting.

Link here to full article

Advanced Oncotherapy (AVO) announces successful RF Power testing of the first CCL unit

AVO1Advanced Oncotherapy (AVO) announces that the Radio Frequency Power tests of the first Coupled Cavity Linac unit have been successfully completed at the Company’s testing facility at CERN in line with expectations.

The RF Power units, created by ScandiNova Systems AB, generate the high-power needed to accelerate protons to speeds whereby they can effectively target cancer cells. The RF Power units include the modulator, for the early delivery of which, our partner ScandiNova accepted part payment in shares as announced on 2 April 2015.

This announcement follows the successful completion in January of the LIGHT system’s first CCL unit, an accelerating structure that consists of a series of cells that accelerate protons from energies of 37.5 Mega-electron Volts (MeV) to the full 230MeV required to treat all radiosensitive tumours.

On 1 May 2015 the Company announced a successful £20m fundraise net of expenses to continue the development of its LIGHT system, with the first unit expected to be installed in Harley Street, London, by the end of 2016 and first patient treatments expected in 2017.

Commenting, Sanjeev Pandya, CEO of Advanced Oncotherapy, said: “In November last year we gave investors a clear pathway towards the delivery of our first LIGHT system and I am delighted that we continue to deliver to this timetable on time and to budget, with the successful RF Power testing of the first CCL unit. Our recent funding has provided the Company with the financial security that we need to deliver our ground-breaking proton therapy technology which we expect will be treating patients in the heart of London in 2017.”

Advanced Oncotherapy Plc
www.avoplc.com
Sanjeev Pandya, CEO
Tel: +44 20 3617 8728
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)

Antonio Bossi / David Coaten
Tel: +44 20 7601 6100
Beaufort Securities (Joint Broker)

Saif Janjua / Jon Levinson
Tel: +44 20 7382 8300
Walbrook PR (Financial PR & IR)
Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy
Mob: +44 7980 541 893 / Mob: +44 7876 741 001

Thomas Cook Shamed Into Action As Shares Fall

Shares in shamed tour operator Thomas Cook fell yesterday by 5p as concern grew about the increasingly hostile reaction of potential customers to the company’s hard hearted attitude over the deaths of two children in 2006 and the findings of a coroners inquest that it had breached its duty of care to the two children.  As soon as the company realised it was  going to face customer resistance and damage to its share price, its attitude miraculously changed.

It made a half hearted apology in public through the media, its executives apparantly lacking the moral fibre to do it  face to face with the family, in private. To try and halt the slide in its share price, it also announced that it had suddenly been overcome with charitable feelings and was making a donation to UNICEF of half of the huge compensation which it had received, now known to be £3 million.

What a pity that the company could not have admitted its role and made a proper apology years ago instead of waiting until it was forced to act in an attempt to stave off the financial consequences of the damage it did to its own reputation and image. And how long can the senior executives responsible for this disgraceful episode  be allowed to remain in office.

HiddenGreece –  villas and houses for sale in Greece – http://www.hiddengreece.net

 

Alan Green discusses Inmarsat (ISAT) with Justin Waite on the ADVFN podcast

 

 

 

Alan Green discusses Inmarsat (ISAT) with Justin Waite on the ADVFN podcast .

Link here to listen

Feedback PLC – Collaboration with the University of Texas MD Anderson Cancer Center, Houston, Texas, USA

FBKlogoFeedback plc (FDBK), the medical imaging software company, is pleased to announce that it has signed a research agreement with The University of Texas MD Anderson Cancer Center in Houston, Texas, USA, to investigate the potential future clinical application of Feedback’s TexRAD texture analysis software on computed tomography (CT) image data of patients with kidney and adrenal cancer. This will be a retrospective study and the results will not be used to influence or guide the treatment regime for existing patients.

The research collaboration will be led by Prof. Haesun Choi (Professor, Department of Diagnostic Radiology, MD Anderson Cancer Center). Prof. Choi is a world leading imaging expert and is renowned for developing the CT based “Choi criteria” for assessing response to anti-vascular therapy extensively used around the world in clinical, research and pharmaceutical drug trials.

Prof. Haesun Choi commented: “Limitations of the size-based traditional response evaluation criteria in solid tumor have been well recognized, particularly, in those treated with the new molecularly targeted agents. More reliable user-friendly biomarkers that can reflect the tumor response and that can be used in risk-stratification are needed. The tumors are known to be heterogeneous in their phenotypes and genotypes. Analyzing the tumor heterogeneity on CT images may provide insights of tumors that may be useful in evaluating the tumor response. MD Anderson Cancer Center currently is exploring of the potential value of this new mean in kidney cancers.”

Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company’s subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented: “Prof. Haesun Choi is one of the top and highly recognized imaging experts based at the very prestigious MD Anderson Cancer Center. For the last 25 years MD Anderson Cancer Center has consistently ranked as one of the USA’s top two cancer centres receiving over 120,000 people last year for care, services and clinical trial. We are delighted that she will be leading the large comprehensive patient population study (around 400 patients with kidney and adrenal cancers) on CT to strengthen the evidence base of TexRAD as the leading tumour texture heterogeneity analysis software. The investigation in kidney and adrenal cancer patient risk-stratification and treatment response evaluation, will potentially lead to the established use of TexRAD in pharmaceutical drug trials and clinical management. Working with MD Anderson Cancer Center will significantly enhance our TexRAD research collaborator base and credibility with the addition of this key site in the USA.”

For further information contact:

Feedback plc
Tel: 01954 718072
Simon Barrell / Trevor Brown / Tom Charlton

Sanlam Securities UK (Nominated Adviser and Joint Broker)
Tel: 020 7628 2200
Simon Clements / Virginia Bull

Peterhouse Corporate Finance Ltd (Joint Broker)
Tel: 020 7469 0936
Lucy Williams / Duncan Vasey

Advanced Oncotherapy – Exercise of Warrants and Issue of Shares and Warrants

Exercise of Warrants

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for treating cancer, announces that it has today issued 5,000,000 new ordinary shares at a subscription price of 1 penny each pursuant to the exercise of warrants.

Issue of Further Shares and Warrants

In accordance with the Supplemental Agreement with Brahma AG announced on 2 April 2015, the Company announces that it has today issued 3,737,169 new ordinary shares and 4,216,293 five year warrants. The Warrants are exercisable at a price of 8.25p per share. The issue of the Further Shares and Warrants fully completes the Company’s obligations under the Agreement.

Admission

Application has been made for the 5,000,000 Warrant Shares and the 3,737,169 Further Shares to be admitted to trading on AIM and it is expected that Admission will occur on 22 May 2015. The Shares will rank pari passu in all respect with the existing Shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 1,347,922,626 Shares, with voting rights. The Company does not hold any Shares in treasury. Therefore the total number of Shares in the Company with voting rights will be 1,347,922,626. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact:

Advanced Oncotherapy Plc
www.avoplc.com
Sanjeev Pandya, CEO
Tel: +44 20 3617 8728
Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten
Tel: +44 20 7601 6100

Beaufort Securities (Joint Broker)
Saif Janjua / Jon Levinson
Tel: +44 20 7382 8300

Walbrook PR (Financial PR & IR)
Tel: +44 20 7933 8780 or avo@walbrookpr.com
Paul McManus / Anna Dunphy
Mob: +44 7980 541 893 / Mob: +44 7876 741 001